| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TR2-C52H4 | Canine | Canine TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-R52H3 | Rhesus macaque / Cynomolgus | Rhesus macaque / Cynomolgus TROP-2 / TACSTD2 Protein, His Tag (MALS verified) |  |
|
|
| TR2-M52H6 | Mouse | Mouse TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-H5253 | Human | Human TROP-2 / TACSTD2 Protein, Fc Tag |  |
|
|
| TR2-H82E5 | Human | Biotinylated Human TROP-2 / TACSTD2 Protein, His,Avitag™ |  |
|
|
| TR2-H5223 | Human | Human TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
Immobilized Human TROP-2, Fc Tag (Cat. No. TR2-H5253) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.2-2 ng/mL (QC tested).
The purity of Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) was more than 85% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | IMMU-132; TROP-2-SN-38 | Approved | Immunomedics Inc | Trodelvy | United States | Triple Negative Breast Neoplasms | s:16:"Immunomedics Inc"; | 2020-04-22 | Carcinoma, Ovarian Epithelial; Carcinoma, Hepatocellular; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Endometrial Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Adenocarcinoma, Follicular; Glioblastoma; Ovarian Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Liver Failure | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SKB-264 | SKB-264 | Phase 2 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| DAC-002 | DAC-002; JS-108 | Phase 1 Clinical | Hangzhou Dac Biotech Co Ltd | Solid tumours; Triple Negative Breast Neoplasms | Details |
| BAT8003 | BAT-8003 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
| datopotamab | DS-1062a; DS-1062; Dato-DXd | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z